|Mr. Jose Maria Fernandez Sousa-Faro||Founder, Exec. Chairman, CEO & Pres||294k||N/A||N/A|
|Mr. Pedro Francisco Fernandez Puentes||Exec. Vice-Chairman||124k||N/A||N/A|
|Mr. Juan Carlos-Torres Carretero||Founder||N/A||N/A||1949|
|Ms. MarÃa Luisa de Francia Caballero||Chief Financial Officer||N/A||N/A||N/A|
|Mr. Pascal Besman||Chief Operating Officer||N/A||N/A||N/A|
|Ms. Elena Calleja Crespo||Director of Fin. & Admin.||N/A||N/A||N/A|
|Mr. JosÃ© Luis Moreno Martinez-Losa||Director of Capital Markets & Investor Relations||N/A||N/A||N/A|
|Ms. Sandra Llamera SÃ¡nchez||Global Compliance Head||N/A||N/A||N/A|
|Ms. Maria Concepcion Sanz||Bus. Legal Director||N/A||N/A||N/A|
|Mr. Juan NoguÃ©s||Director of Marketing and Sales||N/A||N/A||N/A|
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops clinical-stage programs, including PM184 and PM14. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.
Pharma Mar, S.A.’s ISS governance QualityScore as of 26 September 2021 is 6. The pillar scores are Audit: 4; Board: 9; Shareholder rights: 7; Compensation: 4.